LRCC participates in clinical trial for metastatic melanoma | Health
Lakeland, Florida-- Lakeland Regional Cancer Center (LRCC) is proud to have been initiated as the only enrolling site in the eastern United States for a metastatic melanoma clinical trial.
LRCC is now in the process of screening patients.
The trial, which is developed by OncoSec Medical Incorporated, is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks.
One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle.
At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
According to LRCC, Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal.
For more information on this trial or to find out if you are a candidate, please call 863-904-1900.
To learn more about LRCC and its clinical trials program, please visit www.lrmc.com/cancer-center.
Information courtesy of Lakeland Regional Cancer Center